Phenytoin Tablets segmentation by type captures formulation variants that influence prescribing convenience, adherence, and supply‑chain logistics. Immediate‑release tablets dominate the product mix, representing approximately 65 % of unit volume because they provide rapid plasma peaks suitable for acute seizure control and are widely stocked in outpatient pharmacies. Extended‑release tablets, accounting for roughly 20 % of sales, are engineered to maintain steadier serum concentrations over 12–24 hours, thereby reducing dosing frequency for chronic epilepsy management and appealing to patients seeking improved compliance. Chewable tablets, a niche constituting about 8 % of the market, address pediatric and geriatric cohorts with swallowing difficulties, enabling dose flexibility while preserving bioequivalence to the standard tablet. Finally, oral disintegrating tablets (ODTs) hold a modest 7 % share, favored in emergency departments and home‑care settings where rapid dissolution without water is advantageous. These type‑based sub‑segments collectively determine manufacturing complexity, price positioning, and distribution channels, essential elements of the overall Phenytoin Tablets market taxonomy.
